Carlyle Group Inc (CG)
Official siteFINANCIAL SERVICES • ASSET MANAGEMENT • NASDAQ
Market Cap: $14.08B
Last updated: Nov 17, 2026 at 11:05 AM ET
Carlyle Group Inc (CG) Stock Forecast
Analysts expect Carlyle Group (CG) to earn $3.63 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.69B. Of 20 analysts, 10 rate the stock Buy or Strong Buy, 9 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 10 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.40, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 20.0% |
| Buy | 6 | 30.0% |
| Hold | 9 | 45.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.0% |
- Consensus
- Buy
- Total analysts
- 20
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 33.6% and revenue estimates rise 24.9%.
- Fiscal year ending Dec 31, 2026
- $3.63
- EPS consensus, revenue $3.69B
- Fiscal year ending Dec 31, 2027
- $4.85
- EPS consensus, revenue $4.61B
- Next report
- Feb 4, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.63 | $3.57 to $3.70 | 16 | $3.69B | $3.58B to $3.80B | 8 |
| Dec 31, 2027 | $4.85 | $4.35 to $5.25 | 19 | $4.61B | $4.27B to $4.94B | 9 |
Quarterly Estimates
The EPS consensus rises from $0.57 for the quarter ending Dec 31, 2026 to $1.12 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.57 | $0.48 to $0.65 | 21 | $889.47M | $751.66M to $992.25M | 15 |
| Mar 31, 2027 | $1.12 | $1.02 to $1.26 | 12 | $1.08B | $990.00M to $1.15B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 23 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 10 |
| Fiscal year ending Dec 31, 2027 | 2 | 7 |
| Quarter ending Mar 31, 2027 | 0 | 6 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.5% from $3.65.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.63 | $3.50 | $3.59 | $3.67 | $3.65 | -0.6% |
| Fiscal year ending Dec 31, 2027 | $4.85 | $4.95 | $4.98 | $5.11 | $5.11 | -5.2% |
| Quarter ending Mar 31, 2027 | $1.12 | $1.16 | $1.17 | $1.20 | $1.20 | -6.8% |
Frequently Asked Questions About CG
What is the CG stock forecast?
Consensus analyst estimates put Carlyle Group's EPS at $3.63 for the fiscal year ending Dec 31, 2026, on revenue of $3.69B. The consensus rating from 20 analysts is Buy.
How do analysts rate CG stock?
Of 20 analysts covering Carlyle Group, 4 rate it Strong Buy, 6 Buy, 9 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CG next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.63, with estimates from $3.57 to $3.70 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $4.85, with estimates from $4.35 to $5.25 from 19 analysts.
What revenue do analysts expect from Carlyle Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.69B, with estimates from $3.58B to $3.80B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.61B, with estimates from $4.27B to $4.94B.
How many analysts cover CG?
20 analysts rate Carlyle Group stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CG pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors